Heart Matters · Columbus, Ohio · Founded by Sampson Kontomah
The world's first unified AI-powered cardiovascular diagnostics and care platform — detecting, predicting, and preventing heart disease in real time.
01 · The Problem
Cardiovascular disease kills 17M+ people annually and costs the U.S. $400B/year — yet diagnosis remains manual, siloed, and inaccessible.
ECG, imaging, lab results, and wearable data live in separate systems. Clinicians manually synthesize across platforms — a slow, error-prone process where minutes cost lives.
A worsening global cardiologist shortage leaves patients waiting weeks for consultations — by which time preventable cardiac events have already occurred.
Existing AI tools address only one modality — ECG or imaging or risk scores — never the full clinical picture. Clinicians stitch together partial insights from disconnected platforms.
Current cardiology workflows are reactive. There is no infrastructure for continuous, proactive monitoring that predicts and prevents cardiac events before they happen.
A $500B market gap: women are systematically misdiagnosed because no platform incorporates sex-specific CVD risk factors. Heart disease kills more women than all cancers combined.
Hospitals face mounting pressure to reduce costs while improving outcomes. Manual workflows, redundant testing, and prolonged diagnostic timelines drive costs higher every year.
02 · The Solution
Cardio AI's Unified Master Orchestrator synthesizes all cardiac data streams into one intelligent, automated, actionable system.
"No solution today unifies ECG, imaging, biomarkers, IoMT, and risk prediction into one real-time cardiac intelligence platform — until Cardio AI."
The world's first complete cardiovascular AI platform
Central coordination engine with task routing, load balancing, state management, event broadcasting, error recovery, and metrics collection — managing all 5 subsystems in real time.
Dedicated agents for ECG, echocardiography, lab biomarkers, risk assessment (TIMI & GRACE), diagnostic synthesis, personalized treatment, and prognosis & survival analysis.
AI-powered AHA-aligned predictors for AMI, stroke, heart failure, sudden cardiac death, and AFib — with C-statistics up to 0.80, 95% confidence intervals, and 1/5/10-year timeframes.
Real-time continuous cardiac monitoring via MQTT, HTTP, CoAP, and WebSocket protocols — with instant alert generation, anomaly detection, and <1s alert latency.
6 specialized imaging agents for DICOM ingestion, preprocessing, segmentation, quantification, T1/T2 mapping, calcium scoring, and automated HL7-integrated report generation.
The only AI platform incorporating sex-specific risk factors, hormonal influences, and pregnancy-related cardiac conditions — addressing a $500B underserved market no competitor touches.
03 · The Product
From IoMT vitals to final treatment plan — every patient receives a complete, automated cardiac assessment in real time.
Real-time continuous monitoring from wearable devices. Data ingested via MQTT, HTTP, CoAP, and WebSocket protocols with <1s alert latency.
AI-powered STEMI/NSTEMI detection, arrhythmia classification, and ICD-10 coding. 89% diagnostic confidence on echocardiogram analysis.
5 AI-powered CVD risk calculators run simultaneously — AMI, stroke, heart failure, SCD, and AFib — with 95% confidence intervals and AHA Guidelines alignment.
PACS/DICOM platform with 6 specialized agents. EchoFrame model achieves 91.37% Dice score for left ventricle segmentation deployed on GCP Vertex AI.
Evidence-based diagnostic agent synthesizes all data streams — ECG, imaging, labs, biomarkers, and risk scores — into a unified clinical picture with differential diagnosis.
Personalized treatment recommendations, drug dosage optimization, prognosis, survival analysis, and automated report generation with HL7 integration for EHR delivery.
Business Model · PMPM SaaS
Core AI diagnostics
Advanced analytics
Full platform access
IoMT-RPM monitoring
All 4 tiers bundled
04 · Traction
Strong early momentum across clinical validation, commercial pipeline, and technical deployment.
Official clinical validation partner providing rigorous, peer-reviewed evidence to support FDA 510(k) and De Novo submissions across multiple product lines.
FDA 510(k) clearance and De Novo submissions in preparation across multiple AI-powered product lines — establishing first-of-kind regulatory pathways in cardiovascular AI.
AI models deployed on GCP Vertex AI. Full HIPAA-compliant cloud infrastructure operational. EHR/EMR integration frameworks established with Epic and Cerner.
05 · The Team
A team built on 5+ years of shared trust, domain expertise, and proven collaboration — assembled through conviction, not convenience.
15+ years in AI, enterprise technology & cardiovascular medicine. Expert in multi-agent systems. Met the core team through AHA conference and 5+ year relationships. Economics, Ohio State University.
MD, MBA, FACC, FASE. 25+ years as Board-Certified Nuclear Cardiologist. Former Chief Cardiologist at Harlem Hospital. Cardiology fellowships at Yale & Cornell. Met Sampson at AHA conference.
Master's in AI, Rochester Institute of Technology. Built production models: 89% echo confidence, 91.37% LV segmentation Dice score on GCP Vertex AI. 5+ year collaborator with CEO.
Expert in HIPAA-compliant, scalable systems. Specializes in Python, Flask, Django, AWS, and EHR integration using FHIR and HL7. Built telehealth platforms across healthcare and biotech.
Deep expertise in mobile health platforms and iOS/Android development. Translates complex cardiac AI capabilities into intuitive clinical workflows for patients and providers.
Architected Cardio AI's GCP infrastructure from the ground up. Integrated Python-based AI agents with scalable frontend systems. HIPAA-compliant practices embedded across development lifecycle.
PhD, Biomedical Engineering, University of Connecticut. Postdoctoral research at Johns Hopkins & Georgia Tech. Specializes in AI-based AFib detection via wearable technology.
PhD. 8+ years in AI/ML and multi-omics analysis. Led AI projects at UCLA and Truveta. Founder of Mindverse Computing exploring quantum computing applications in healthcare.
Venture & Healthcare Technology expert focused on investment partnerships, fundraising, and financial strategy. Brings deep expertise in structuring healthcare investment deals and capital formation. Holds a Juris Doctor from the University of Wisconsin.
Finance executive with 10+ years across venture capital, investment banking, and consulting. Leads financial strategy, fundraising, and scaling operations with a strong mix of investor insight and hands-on operator experience. MBA, Georgetown University · BSBA Economics & Finance, University of Hartford.
06 · Financial Projections
PMPM SaaS model with 45-50% EBITDA margins at scale. Self-sustaining growth from a single seed round.
Self-sustaining growth from Year 1 cash generation. Optional Series B for international expansion only. No bridge financing required.
Customer LTV of $7,584 with payback period under 3 months and churn below 5% — world-class SaaS unit economics driven by sticky clinical workflows.
AI platform scales from 25K to 1.2M members without proportional cost increases. Revenue per employee grows from $0.68M to $9M+ over 5 years.
07 · Go-To-Market
A disciplined, phased go-to-market strategy moving from clinical validation to regional expansion to national payer-driven scale.
08 · Competitive Landscape
Every competitor addresses 1-3 cardiac modalities. Cardio AI is the only fully integrated cardiac intelligence platform.
| Company | ECG | Imaging | Treatment | Remote Mon. | CVD Risk | Women's CVD | AI Agents |
|---|---|---|---|---|---|---|---|
| ⭐ Cardio AI | YES | ALL | YES | YES | 5 AI | YES | 8 |
| Eko Health | YES | NO | NO | NO | NO | NO | 2 |
| Cleerly | NO | CT | NO | NO | NO | NO | 1 |
| Ultromics | NO | MRI | NO | NO | NO | NO | 2 |
| Viz.ai | NO | CT | NO | NO | NO | NO | 2 |
| Tempus | NO | Part | YES | NO | NO | NO | 3 |
| Alive Cor | YES | NO | NO | YES | NO | NO | 2 |
Competitive Advantages
Only platform addressing sex-specific CVD risk factors in a $500B underserved market. No competitor has built this.
No competitor has a central engine synthesizing all cardiac data modalities simultaneously. Every other solution is a point product.
Screening → Diagnosis → Treatment → Monitoring. The only platform that follows a patient through the entire cardiac care journey.
Seamless Epic/Cerner EHR integration, multi-protocol IoMT wearable support, and PACS/DICOM compatibility removes the biggest adoption barrier in healthtech.
09 · Roadmap
Six critical milestones on the path to becoming the global standard for cardiovascular AI.
Finalize active pilots across 5 university medical center partners and health systems — generating real-world clinical performance data across diverse patient populations.
Compile and analyze validation data through DatosX and university medical center partnerships — building the rigorous evidence base required for regulatory submission.
Submit and obtain 510(k) clearance for initial product lines — establishing regulatory credibility and formal market access for AI-assisted cardiovascular diagnostics.
File De Novo submissions across multiple novel AI-powered product lines — securing first-of-kind regulatory pathways for our most innovative diagnostic capabilities.
Execute full commercial launch targeting hospitals, community hospitals, health systems, and payers across all four PMPM pricing tiers with full EHR integration.
Activate 5 LOIs, convert 380 early adopters, and scale toward 25,000+ members and $25M+ revenue in Year 1 — fully self-funded from seed round.
10 · Clinical Use Cases
From pregnancy monitoring to high-risk cardiac events — Cardio AI delivers measurable clinical impact across the full spectrum of cardiovascular care.
Women's CVD Platform
BP 165/105 detected → AI: 89.2% preeclampsia risk → Tier 2 physician alert → MFM consult triggered → Early intervention initiated.
Non-specific symptoms → AI flags atypical pattern → Troponin 0.8 ng/mL elevated → SCAD evaluation triggered → Angiography confirms diagnosis.
Progressive dyspnea → Echo: LVEF 38% → PPCM diagnosed → Heart failure protocol started → Cardiology follow-up coordinated.
High-Risk Patient · Real-Time AI Response
Symptoms: Chest pain, dyspnea
History: T2 diabetes, hypertension
Setting: Community cardiology clinic
Prior Dx: Anxiety — misdiagnosed ×6 months
ECG, echo, labs, and EHR history ingested simultaneously by the Master Orchestrator
8 agents detect silent ST-depression, elevated TIMI score & microvascular ischemia — missed for 6 months
Cardiologist notified in real-time; cath lab placed on standby
NSTEMI confirmed; previously misdiagnosed as anxiety for 6 months
Personalized dual-antiplatelet protocol pushed directly into EHR workflow
IoMT wearable tracks post-procedure recovery; 30-day readmission risk updated daily
IoMT Clinical Workflow
Post-discharge heart failure monitoring with daily vitals, AI trend analysis, and early intervention to reduce 30-day readmissions. 7-agent pipeline processes continuous RPM data streams.
Population-level AFib detection using continuous ECG monitoring with >95% confidence, enabling early stroke prevention and anticoagulation therapy guidance.
Post-MI rehab with real-time HR/rhythm monitoring, AI-detected arrhythmias, automatic safety interventions, and progress tracking via IoMT wearable integration.
200 tests passing · 7 active AI agents · 3-way HMAC-SHA256 + JWT authentication · 16 WebSocket protocol message types · Real-time RPM data pipeline
11 · Long-Term Vision
"A world where no cardiac event goes undetected, no patient falls through the cracks, and every clinician has the intelligence needed to save lives."
Sampson Kontomah · Founder & CEO · Cardio AI
Bringing AI-powered cardiac intelligence to underserved markets across Africa, Asia, and Latin America — where CVD burden is highest and specialist access is lowest.
Shifting from reactive treatment to proactive, continuous cardiac monitoring that predicts and prevents events before they occur — redefining the standard of care.
As the only platform addressing sex-specific CVD risk, Cardio AI will redefine how women's heart disease is detected, treated, and prevented globally.
Becoming the cardiac intelligence layer for every major health system, payer, and EHR platform globally — embedded in the infrastructure of modern healthcare.
12 · Company Valuation
A rigorous, data-driven valuation anchored to 2025–2026 market benchmarks, comparable transactions, and three independent methodologies. Based on publicly available market data as of March 2026.
Market Context
Growing at 31.17% CAGR from $1.69B in 2025. North America holds 46.79% share.
AI-enabled healthcare startups raised an 83% premium over non-AI startups. Avg deal: $26.1M.
Healthcare AI valuations grew 63% YoY in 2025. AI-services companies command 70–80%+ gross margins.
Cardio AI is the only platform addressing sex-specific CVD risk factors. Zero direct competition in this category.
Comparable Companies · 2025–2026
| Company | Focus | Stage | Valuation | Raised |
|---|---|---|---|---|
| HeartFlow (HTFL) | AI cardiac diagnostics (CAD/CCTA) | Public · IPO Aug 2025 | $2.2B | $364M |
| Viz.ai | AI disease detection & care coordination | Series D | $1.2B | $252M |
| AliveCor | AI ECG / wearable cardiac monitoring | Series F | ~$300–400M | $114M |
| Cleerly | AI coronary CT imaging | Private | ~$500M | $223M |
| Abridge | AI clinical documentation | Series E | $5B | $300M |
| OpenEvidence | AI clinical search & evidence | Late Stage | $12B | $250M+ |
| ⭐ Cardio AI (Subject) | Unified multi-modal cardiac AI platform | Seed · Pre-Revenue | $50M–$80M | $5M |
Three Valuation Methodologies
DCF Model · 5-Year Projections (2027–2031)
| Year | Revenue | EBITDA (48%) | Discount (40%) | Present Value |
|---|---|---|---|---|
| 2027 — Year 1 | $25M | $11M | 0.71 | $7.8M |
| 2028 — Year 2 | $150M | $68M | 0.51 | $34.7M |
| 2029 — Year 3 | $600M | $288M | 0.36 | $103.7M |
| 2030 — Year 4 | $1.1B | $550M | 0.26 | $143.0M |
| 2031 — Year 5 | $1.9B | $950M | 0.19 | $180.5M |
| Sum of PV Cash Flows + Terminal Value (10x Yr5 EBITDA) | ~$650M | |||
Premium Factors ↑
Discount Factors ↓
Value Creation Milestones
Real-world clinical performance data across diverse patient populations. +$20–$30M valuation impact
Formal regulatory pathway established. Triggers re-rating by investors. +$50–$100M valuation impact
Transitions from pre-revenue to revenue multiple pricing. +$100–$200M valuation impact
Commercial deployment unlocked. Payer reimbursement pathway opens. +$150–$300M valuation impact
Category-defining regulatory approval. Zero competition in this category. +$200–$400M valuation impact
Breakout re-rating to HeartFlow comparable range. $800M – $1.2B total valuation
Recommended Raise Strategy
Implied post-money: $50–$80M · Dilution: 6–10%
Complete pilots, FDA prep, core team expansion.
Implied post-money: $150–$250M · Dilution: 10–15%
FDA submission, GTM launch, payer pipeline activation.
Implied post-money: $400–$650M · Dilution: 8–12%
Scale sales, payer partnerships, international expansion.
Contact our investor relations team to request our full financial model, due diligence package, and investor deck.
This valuation is based on publicly available market data as of March 2026. Not investment advice. Engage a licensed financial advisor for formal valuation opinion.